Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Multiple Myeloma Market 2030 Forecasts in 2016 Research Report

Market Reports Online
Posted on: 31 Aug 16

PR Newswire

PUNE, Maharashtra, August 31, 2016

PUNE, Maharashtra, August 31, 2016 /PRNewswire/ --

MarketReportsOnline.com adds "Global Multiple Myeloma Market: Industry Analysis & Outlook (2016-2030)" research that offers a comprehensive analysis of the multiple myeloma market covering dynamics such as key trends and development; and challenges are analyzed in depth. On the contention front, the global market is reined by few major players namely Johnson & Johnson, Roche Holding, Sanofi and Novartis. The competitive landscape of the respective market, along with the company profiles of the leading players are also discussed in detail.

Complete report on multiple myeloma market spread across 53 pages providing 4 company profiles and 3 tables and 34 charts is now available at http://www.marketreportsonline.com/496437.html.

Multiple Myeloma is a form of blood cancer. Blood cancers, or hematologic cancers, affect the production and function of blood cells. Most of these cancers start in the bone marrow where blood is produced. In myeloma, unusually large numbers of abnormal plasma cells gather in bone marrow and stop it from producing an important part of your immune system. Multiple myeloma is a cancer formed by malignant plasma cells. Multiple myeloma is characterized with low blood counts, bone and calcium problems, infections, kidney problems and nervous system symptoms. Usually the age factor is considered as the most prominent factor in multiple myeloma cases.

Company coverage of Multiple Myeloma Market: Johnson & Johnson, Roche Holding, Sanofi & Novartis

Multiple myeloma was considered to be a non-treatable disease but hopes have arrived with the approval of Darzalex which was a much awaited product and has shown positive results in the trials. Many other products are in the pipeline and will arrive after some time. Darzalex is an antibody with immense potential and was the first monoclonal antibody approved by the FDA for the treatment of heavily pretreated retreated multiple myeloma. More experiments have started to check out Darzalex in combinations to find out its effectiveness in case of other problems too.

The key factors which are anticipated to drive multiple myeloma market include increased penetration of cancer drugs, increase in ageing population, rising obese population and increase in healthcare expenditure. Some of the significant developments of this industry include upcoming new innovative products in the market, trend of combination therapies, and chance of new players. However, the challenge to be faced ahead is high price and legal regulations.

Order a copy of this "Global Multiple Myeloma Market" research report at http://www.marketreportsonline.com/contacts/purchase.php?name=496437.

Key Topics Covered in Multiple Myeloma Market Report: 

1. Blood Cancer: An Introduction

2. Multiple Myeloma

3. Multiple Myeloma Market Analysis

4. Regional Markets

5. Market Dynamics

6. Competitive Landscape

7. Key Product Analysis

8. Company Profiles

Few Points from List of Charts: 

Types of Blood Cancer

Global Blood Cancer Market Forecast by Value (2015/2020)

Global Multiple Myeloma Market Forecast by Value (2016-2030)

Global Forefront Treated Patients Forecast (2016-2030)

Global Reverted Treated Patients Forecast (2016-2030)

The US Multiple Myeloma Market Forecast by Value (2016-2030)

The US Forefront Treated Patients Forecast (2016-2030)

The US Reverted Treated Patients Forecast (2016-2030)

Europe Multiple Myeloma Market Forecast by Value (2016-2030)

Europe Forefront Treated Patients Forecast (2016-2030)

Europe Reverted Treated Patients Forecast (2016-2030)

ROW Multiple Myeloma Market Forecast by Value (2016-2030)

ROW Forefront Treated Patients Forecast (2016-2030)

ROW Reverted Treated Patients Forecast (2016-2030)

Other Related Report on Multiple Myeloma Market: 

Global Multiple Myeloma Partnering 2010 to 2016 : The report provides an analysis of partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right t- license the licensors technology. These deals tend t- be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight int- the negotiation process in terms of what you can expect t- achieve during the negotiation of terms.

Explore more pharmaceuticals market research as well as other newly published reports by Koncept Analytics at http://www.marketreportsonline.com/publisher/koncept-analytics-market-research.html.

About Us:  

Market Reports Online comprises of an online library of 250,000 reports and in-depth market research studies of over 5000+ micro markets. We provide 24/7 online and offline support to our customers. Get in touch with us for your needs of market research reports.

Contact Us:
Ritesh Tiwari
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune, Maharashtra 411013, India
Tel: + 1 888 391 5441
E-mail: sales@marketreportsonline.com

SOURCE Market Reports Online

PR Newswire
www.prnewswire.com

Last updated on: 31/08/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.